What's in Elite Laboratories, Inc's pipeline?

Elite Laboratories, Inc has 3 drugs in our index: 0 marketed, 0 filed, 3 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Elite Laboratories, Inc's portfolio?

Top competitors by shared drug class: Alkermes, Inc., Indivior Inc., Johns Hopkins University, Merck Sharp & Dohme LLC, New York State Psychiatric Institute.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/elite-laboratories-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-06-10 · How we verify

Elite Laboratories, Inc — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Elite Laboratories, Inc pipeline: 0 marketed, 0 filed, 3 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 3 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Oxycodone/Naltrexone Capsules	Oxycodone/Naltrexone Capsules	phase 3	opioid analgesic with abuse-deterrent properties	mu-opioid receptors	Pain Management
Oxycodone Naltrexone (a)	Oxycodone Naltrexone (a)	phase 3	Opioid agonist-antagonist combination	Mu-opioid receptor (oxycodone agonist); opioid receptors (naltrexone antagonist)	Pain Management
Oxycodone Naltrexone (b)	Oxycodone Naltrexone (b)	phase 3	Opioid agonist-antagonist combination	Mu-opioid receptor (oxycodone); opioid receptors (naltrexone antagonism)	Pain Management

Therapeutic area mix

Pain Management · 3

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Alkermes, Inc. · 1 shared drug class
Indivior Inc. · 1 shared drug class
Johns Hopkins University · 1 shared drug class
Merck Sharp & Dohme LLC · 1 shared drug class
New York State Psychiatric Institute · 1 shared drug class
Orexo AB · 1 shared drug class
The University of Texas Health Science Center, Houston · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Elite Laboratories, Inc:

Cite this brief

Drug Landscape (2026). Elite Laboratories, Inc — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/elite-laboratories-inc. Accessed 2026-06-10.